issuance of new debentures. Meanwhile, interest expense on deposits increased by 7.5% from the increased in deposit amount by 20.9% yoy consistent with the growth in overall loan portfolio. The cost of fund
from the 1Q19 catalyst turnaround at our EO-EG facility in USA and due to the plummeting MEG margins in Asia although cushioned by the lower cost USGC economics. On the other hand, our Purified EO (PEO
approved the sale of Takuni Land’s shares including approved Takuni Land to purchase the land from a director of the company to be as an access road for the Project (which included in the development cost
business in 1Q2018 decreased from lower selling price of processed food which decreased by 9.70% comparing to 1Q2017. Cost of Sales Cost of sales for 1Q2018 was THB 3,439.11 million, a slight decrease of THB
disposal of assets - 0.0% 174 0.3% (174) (100.0%) Other income(1) 3,419 6.4% 3,282 6.5% 137 4.2% Total revenue 53,444 100.0% 50,307 100.0% 3,137 6.2% Cost of sales of goods 34,980 65.5% 32,724 65.0% 2,257
million) YoY YoY Operating Revenue 251 283 13% 871 1,194 37% Cost of sales (89) (102) 15% (289) (421) 46% Gross Profit 162 181 12% 582 773 33% Other Income 3 4 33% 9 11 22% Selling and distribution expenses
hospital operations 8,880.5 8,073.3 807.2 10.0 Revenue from general patients 5,791.1 5,051.6 739.5 14.6 Revenue from Social Security patients 3,089.4 3,021.7 67.7 2.2 Cost of hospital operations (6,052.2
target group to attract the trials for future sales and cost reductions particularly in redundant procedures to deliver appropriate rate of return on sales. ICUK also continued to bear fruit from
growth through priority channels, strong push of product sampling experiences among the target group to attract the trials for future sales and cost reductions particularly in redundant procedures to